{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:10:00Z","timestamp":1761646200185,"version":"build-2065373602"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,28]]},"DOI":"10.7759\/cureus.95564","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:02:17Z","timestamp":1761645737000},"source":"Crossref","is-referenced-by-count":0,"title":["Giant Prolactinoma Resistant to High-Dose Cabergoline in a Young Male Lost to Follow-Up"],"prefix":"10.7759","author":[{"given":"Anoushka","family":"Das","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Adjmal","family":"Rummun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anindya","family":"Shams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Salman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Pituitary adenoma","author":"Russ S","year":"2025","unstructured":"Russ S, Anastasopoulou C, Shafiq I. Pituitary adenoma. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2025."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.19699","article-title":"Diagnosis and treatment of pituitary adenomas: a review","volume":"317","author":"Molitch ME","year":"2017","unstructured":"Molitch ME. Diagnosis and treatment of pituitary adenomas: a review. JAMA. 2017, 317:516-24. 10.1001\/jama.2016.19699","journal-title":"JAMA"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-15-0189","article-title":"The epidemiology of pituitary adenomas in Iceland, 1955-2012: a nationwide population-based study","volume":"173","author":"Agustsson TT","year":"2015","unstructured":"Agustsson TT, Baldvinsdottir T, Jonasson JG, et al.. The epidemiology of pituitary adenomas in Iceland, 1955-2012: a nationwide population-based study. Eur J Endocrinol. 2015, 173:655-64. 10.1530\/EJE-15-0189","journal-title":"Eur J Endocrinol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2014.01.005","article-title":"Visual acuity and pattern of visual field loss at presentation in pituitary adenoma","volume":"21","author":"Ogra S","year":"2014","unstructured":"Ogra S, Nichols AD, Stylli S, Kaye AH, Savino PJ, Danesh-Meyer HV. Visual acuity and pattern of visual field loss at presentation in pituitary adenoma. J Clin Neurosci. 2014, 21:735-40. 10.1016\/j.jocn.2014.01.005","journal-title":"J Clin Neurosci"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2022.11.002","article-title":"A retrospective cohort study assessing geometrical parameters related to visual deterioration in pituitary macroadenoma","volume":"107","author":"Garcia Redmond J","year":"2023","unstructured":"Garcia Redmond J, Maclachlan LR, Barber J, et al.. A retrospective cohort study assessing geometrical parameters related to visual deterioration in pituitary macroadenoma. J Clin Neurosci. 2023, 107:1-7. 10.1016\/j.jocn.2022.11.002","journal-title":"J Clin Neurosci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3171\/jns.2002.97.2.0299","article-title":"Giant prolactinomas: clinical management and long-term follow up","volume":"97","author":"Shrivastava RK","year":"2002","unstructured":"Shrivastava RK, Arginteanu MS, King WA, Post KD. Giant prolactinomas: clinical management and long-term follow up. J Neurosurg. 2002, 97:299-306. 10.3171\/jns.2002.97.2.0299","journal-title":"J Neurosurg"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12242","article-title":"Giant prolactinomas: the therapeutic approach","volume":"79","author":"Moraes AB","year":"2013","unstructured":"Moraes AB, Silva CM, Vieira Neto L, Gadelha MR. Giant prolactinomas: the therapeutic approach. Clin Endocrinol (Oxf). 2013, 79:447-56. 10.1111\/cen.12242","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1159\/000495775","article-title":"Management of dopamine agonist-resistant prolactinoma","volume":"109","author":"Maiter D","year":"2019","unstructured":"Maiter D. Management of dopamine agonist-resistant prolactinoma. Neuroendocrinology. 2019, 109:42-50. 10.1159\/000495775","journal-title":"Neuroendocrinology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-024-01383-2","article-title":"Impulse control disorders in patients with dopamine agonist-treated pituitary adenomas: a cross-sectional multicenter study","volume":"27","author":"Almalki MH","year":"2024","unstructured":"Almalki MH, Alsuraikh MA, Almalki E, et al.. Impulse control disorders in patients with dopamine agonist-treated pituitary adenomas: a cross-sectional multicenter study. Pituitary. 2024, 27:197-203. 10.1007\/s11102-024-01383-2","journal-title":"Pituitary"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-025-01517-0","article-title":"Impulse control disorders in patients with pituitary adenoma managed with or without dopamine agonists: a cross-sectional study from a UK centre","volume":"28","author":"Hamblin R","year":"2025","unstructured":"Hamblin R, White M, Fountas A, Karavitaki N. Impulse control disorders in patients with pituitary adenoma managed with or without dopamine agonists: a cross-sectional study from a UK centre. Pituitary. 2025, 28:52. 10.1007\/s11102-025-01517-0","journal-title":"Pituitary"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz076","article-title":"Impulse control disorders in dopamine agonist-treated hyperprolactinemia: prevalence and risk factors","volume":"105","author":"De Sousa SM","year":"2020","unstructured":"De Sousa SM, Baranoff J, Rushworth RL, et al.. Impulse control disorders in dopamine agonist-treated hyperprolactinemia: prevalence and risk factors. J Clin Endocrinol Metab. 2020, 105:e108-18. 10.1210\/clinem\/dgz076","journal-title":"J Clin Endocrinol Metab"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2019.05.249","article-title":"Radiographic and hormonal regression in prolactinomas: an analysis of treatment failure","volume":"129","author":"Akinduro OO","year":"2019","unstructured":"Akinduro OO, Lu VM, Izzo A, et al.. Radiographic and hormonal regression in prolactinomas: an analysis of treatment failure. World Neurosurg. 2019, 129:e686-94. 10.1016\/j.wneu.2019.05.249","journal-title":"World Neurosurg"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1055\/a-1247-4908","article-title":"Outcomes of transsphenoidal microsurgery for prolactinomas: a contemporary series of 162 cases","volume":"129","author":"Giese S","year":"2021","unstructured":"Giese S, Nasi-Kordhishti I, Honegger J. Outcomes of transsphenoidal microsurgery for prolactinomas: a contemporary series of 162 cases. Exp Clin Endocrinol Diabetes. 2021, 129:163-71. 10.1055\/a-1247-4908","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0058","article-title":"Use of radiotherapy after pituitary surgery for non-functioning pituitary adenomas","volume":"181","author":"Chanson P","year":"2019","unstructured":"Chanson P, Dormoy A, Dekkers OM. Use of radiotherapy after pituitary surgery for non-functioning pituitary adenomas. Eur J Endocrinol. 2019, 181:D1-13. 10.1530\/EJE-19-0058","journal-title":"Eur J Endocrinol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad174","article-title":"Approach to the patient with prolactinoma","volume":"108","author":"Auriemma RS","year":"2023","unstructured":"Auriemma RS, Pirchio R, Pivonello C, Garifalos F, Colao A, Pivonello R. Approach to the patient with prolactinoma. J Clin Endocrinol Metab. 2023, 108:2400-23. 10.1210\/clinem\/dgad174","journal-title":"J Clin Endocrinol Metab"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa652","article-title":"Predictors of the response to dopaminergic therapy in patients with prolactinoma","volume":"105","author":"Hage C","year":"2020","unstructured":"Hage C, Salvatori R. Predictors of the response to dopaminergic therapy in patients with prolactinoma. J Clin Endocrinol Metab. 2020, 105:e4558-66. 10.1210\/clinem\/dgaa652","journal-title":"J Clin Endocrinol Metab"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa882","article-title":"Incidence of cabergoline-associated valvulopathy in primary care patients with prolactinoma using hard cardiac endpoints","volume":"106","author":"Stiles CE","year":"2021","unstructured":"Stiles CE, Lloyd G, Bhattacharyya S, Steeds RP, Boomla K, Bestwick JP, Drake WM. Incidence of cabergoline-associated valvulopathy in primary care patients with prolactinoma using hard cardiac endpoints. J Clin Endocrinol Metab. 2021, 106:e711-20. 10.1210\/clinem\/dgaa882","journal-title":"J Clin Endocrinol Metab"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-2254","article-title":"A cross-sectional study of the prevalence of cardiac valvular abnormalities in hyperprolactinemic patients treated with ergot-derived dopamine agonists","volume":"99","author":"Drake WM","year":"2014","unstructured":"Drake WM, Stiles CE, Howlett TA, Toogood AA, Bevan JS, Steeds RP. A cross-sectional study of the prevalence of cardiac valvular abnormalities in hyperprolactinemic patients treated with ergot-derived dopamine agonists. J Clin Endocrinol Metab. 2014, 99:90-6. 10.1210\/jc.2013-2254","journal-title":"J Clin Endocrinol Metab"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.579606","article-title":"Depression and impulsivity self-assessment tools to identify dopamine agonist side effects in patients with pituitary adenomas","volume":"11","author":"Hinojosa-Amaya JM","year":"2020","unstructured":"Hinojosa-Amaya JM, Johnson N, Gonz\u00e1lez-Torres C, Varlamov EV, Yedinak CG, McCartney S, Fleseriu M. Depression and impulsivity self-assessment tools to identify dopamine agonist side effects in patients with pituitary adenomas. Front Endocrinol (Lausanne). 2020, 11:579606. 10.3389\/fendo.2020.579606","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ando.2020.12.008","article-title":"The risks of medical treatment of prolactinoma","volume":"82","author":"Castinetti F","year":"2021","unstructured":"Castinetti F, Albarel F, Amodru V, et al.. The risks of medical treatment of prolactinoma. Ann Endocrinol (Paris). 2021, 82:15-9. 10.1016\/j.ando.2020.12.008","journal-title":"Ann Endocrinol (Paris)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/416467-giant-prolactinoma-resistant-to-high-dose-cabergoline-in-a-young-male-lost-to-follow-up","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:02:17Z","timestamp":1761645737000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/416467-giant-prolactinoma-resistant-to-high-dose-cabergoline-in-a-young-male-lost-to-follow-up"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,28]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.95564","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,28]]}}}